Anti-tumor activity in preclinical models utilizing a conditional bispecific redirected activation molecule (COBRA) targeting Her2

被引：1
|
作者：
Stringer, Bradley
Chouitar, Johara
Cerbone, Jacqualine
Fortin, Sarah
Ainbinder, Alina
Kysilovsky, Cassie
Scott, Brittany
Banerjee, Antara
机构：
来源：
CANCER RESEARCH | 2024年 / 84卷 / 07期
关键词：
D O I：
10.1158/1538-7445.AM2024-LB063
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
LB063
引用
收藏
页数：2
相关论文
共 50 条
  • [11] RADIATION PRIMING IMPROVES THE ANTI-TUMOR ACTIVITY OF HER2 CAR T CELLS IN GLIOBLASTOMA
    Mullikin, Dolores
    Joseph, Sujith
    Mathew, Pretty
    Salsman, Vita
    Sanber, Khaled
    Lindsay, Holly
    Chakraborty, Rikhia
    Gaber, Waleed
    Ahmed, Nabil
    Hegde, Meena
    PEDIATRIC BLOOD & CANCER, 2019, 66
  • [12] Preclinical activity of MCLA-128, an ADCC enhanced bispecific IgG1 antibody targeting the HER2: HER3 heterodimer
    Geuijen, Cecile
    Rovers, Eric
    Nijhuis, Roy
    den Blanken-Smit, Renate
    Visser, Therese
    Bartelink, Willem
    Kramer, Arjen
    Zondag-van der Zande, Vanessa
    Clements, Carina
    Kaldenberg, Linda
    Nieuwenhuizen, Nellie
    van Loo, Pieter Fokko
    Roovers, Rob
    Gallenne, Tristan
    Price, Leo
    Shamsili, Setareh Van Driel
    Bakker, Lex
    Logtenberg, Ton
    de Kruif, John
    Throsby, Mark
    JOURNAL OF CLINICAL ONCOLOGY, 2014, 32 (15)
  • [13] HER2 specific tumor targeting with dendrimer conjugated anti-HER2 mAb
    Shukla, Rameshwer
    Thomas, Thommey P.
    Peters, Jennifer L.
    Desai, Ankur M.
    Kukowska-Latallo, Jolanta
    Patri, Anil K.
    Kotlyar, Alina
    Baker, James R., Jr.
    BIOCONJUGATE CHEMISTRY, 2006, 17 (05) : 1109 - 1115
  • [14] Bispecific CD3/HER2 Targeting FynomAb Induces Redirected T Cell-Mediated Cytolysis with High Potency and Enhanced Tumor Selectivity
    Wuellner, Ulrich
    Klupsch, Kristina
    Buller, Fabian
    Attinger-Toller, Isabella
    Santimaria, Roger
    Zbinden, Irene
    Henne, Patricia
    Grabulovski, Dragan
    Bertschinger, Julian
    Brack, Simon
    ANTIBODIES, 2015, 4 (04) : 426 - 440
  • [15] Ridaforolimus improves the anti-tumor activity of dual HER2 blockade in uterine serous carcinoma in vivo models with HER2 gene amplification and PIK3CA mutation
    Hernandez, Silvia F.
    Chisholm, Sarah
    Borger, Darrell
    Foster, Rosemary
    Rueda, Bo R.
    Growdon, Whitfield B.
    GYNECOLOGIC ONCOLOGY, 2016, 141 (03) : 570 - 579
  • [16] A bispecific single-chain Fv molecule targeting HER2 and HER3 exhibits tumor-targeting specificity in vivo and a therapeutic effect in vitro.
    Robinson, MK
    Russeva, M
    Horak, EM
    Heitner, T
    Simmons, HH
    Shaller, CC
    Reid, M
    Hodge, K
    Garrison, J
    Tesfaye, A
    Marks, JD
    Weiner, LM
    Adams, GP
    CLINICAL CANCER RESEARCH, 2005, 11 (24) : 8983S - 8983S
  • [17] Anti-tumor effect of afatinib, an irreversible EGFR/HER2 dual inhibitor, in lung cancers harboring HER2 oncogene
    Suzawa, Ken
    Toyooka, Shinichi
    Sakaguchi, Masakiyo
    Ohtsuka, Tomoaki
    Watanabe, Mototsugu
    Hashida, Shinsuke
    Maki, Yuho
    Yamamoto, Hiromasa
    Soh, Junichi
    Asano, Hiroaki
    Tsukuda, Kazunori
    Miyoshi, Shinichiro
    CANCER RESEARCH, 2015, 75
  • [18] Anti-tumor activity of the ATR inhibitor AZD6738 in HER2 positive breast cancer cells
    Kim, Hee-Jun
    Min, Ahrum
    Im, Seock-Ah
    Jang, Hyemin
    Lee, Kyung Hun
    Lau, Alan
    Lee, Miso
    Kim, Seongyeong
    Yang, Yaewon
    Kim, Jungeun
    Kim, Tae Yong
    Oh, Do-Youn
    Brown, Jeffrey
    O'Connor, Mark J.
    Bang, Yung-Jue
    INTERNATIONAL JOURNAL OF CANCER, 2017, 140 (01) : 109 - 119
  • [19] Ridaforolimus improves the anti-tumor activity of dual HER2 blockade in uterine serous carcinoma in vivo models with HER2 gene amplification and a gain of function mutation in PIK3CA
    Growdon, Whitfield
    Hernandez, Silvia F.
    Chisholm, Sarah
    Borger, Darrell
    Foster, Rosemary
    Rueda, Bo R.
    GYNECOLOGIC ONCOLOGY, 2015, 139 (03) : 597 - 597
  • [20] BL-M07D1, a novel HER2-targeting ADC, demonstrates potent anti-tumor efficacy in preclinical pharmacodynamic models
    Wan, Weili
    Zhao, Shuwen
    Zhuo, Shi
    Zhang, Yong
    Chen, Lan
    Li, Gangrui
    Khalili, Jahan Salar
    Xiao, Sa
    Yan, Yongqi
    Shen, Xuejiao
    Zhu, Yi
    CANCER RESEARCH, 2023, 83 (07)
12345